Loading...

PRTA PROTHENA CORP PUBLIC LTD CO Other Situations 8-K Filing

PRTH

PRT

PROTHENA CORP PUBLIC LTD CO

(PRTA)

2025 8-K

Director Resignation

Capital Reduction Approved

Financial Results Released

Drug Update Announcement

Product Expansion

Financial Statements

Management Changes

Product Expansion

Product Discontinuation

Financial Statements

Financial Results

Director Resignation

Q3 Financial Results

Management Change

Financial Results Announcement

Annual Meeting Approval

Earnings Reports

Appointment of Director

Earnings Release

Financial Update

Earnings Release

Earnings Release

Annual Meeting Approval

Appointment of Director

Earnings Release

Resignation of Director

Regulation FD Disclosure

Earnings Report

External Links:

On August 27, 2025, Prothena Corporation announced results from its Phase 1 ASCENT clinical program for the investigational drug PRX012 in a press release attached to its 8-K filing.

AI Assistant

PROTHENA CORP PUBLIC LTD CO

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.